Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

IKT

Inhibikase Therapeutics Inc

May 17 • 04:00PM ET

1.73

Dollar change -0.03
Percentage change -1.70	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.37	Insider Own	13.85%	Shs Outstand	6.19M	Perf Week	32.06%
Market Cap	11.21M	Forward P/E	-	EPS next Y	-1.44	Insider Trans	0.00%	Shs Float	5.58M	Perf Month	-17.62%
Income	-19.20M	PEG	-	EPS next Q	-0.56	Inst Own	6.71%	Short Float	2.42%	Perf Quarter	-26.69%
Sales	0.20M	P/S	56.05	EPS this Y	43.42%	Inst Trans	-20.59%	Short Ratio	2.08	Perf Half Y	84.04%
Book/sh	1.05	P/B	1.65	EPS next Y	28.71%	ROA	-97.88%	Short Interest	0.14M	Perf Year	-56.31%
Cash/sh	1.50	P/C	1.15	EPS next 5Y	-	ROE	-119.64%	52W Range	0.79 - 4.35	Perf YTD	36.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.31%	ROI	-280.92%	52W High	-60.24%	Beta	1.40
Dividend TTM	-	Quick Ratio	2.55	Sales past 5Y	49.79%	Gross Margin	8.71%	52W Low	118.99%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	2.55	EPS Y/Y TTM	19.02%	Oper. Margin	-10285.34%	RSI (14)	51.44	Volatility	18.98% 14.88%
Employees	8	Debt/Eq	0.03	Sales Y/Y TTM	38.08%	Profit Margin	-9797.30%	Recom	1.00	Target Price	17.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	24.91%	Payout	-	Rel Volume	0.71	Prev Close	1.76
Sales Surprise	-	EPS Surprise	7.59%	Sales Q/Q	-100.00%	Earnings	May 16 BMO	Avg Volume	65.03K	Price	1.73
SMA20	12.05%	SMA50	-10.52%	SMA200	0.56%	Trades		Volume	46,035	Change	-1.70%

May-16-24 06:52AM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.56%
May-15-24 08:00PM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire) +29.22%
08:45AM	Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement (GlobeNewswire)
May-09-24 08:00AM	Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-18-24 04:30PM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
08:05AM	Loading…
Apr-03-24 08:05AM	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-02-24 10:25AM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 09:06PM	Q4 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.09%
Mar-27-24 10:53PM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:15PM	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-07-24 08:30AM	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (GlobeNewswire)
Feb-28-24 04:05PM	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Feb-15-24 09:55AM	Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now (Zacks) -6.69%
Feb-07-24 07:55AM	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers (GlobeNewswire) -8.72%
Jan-29-24 09:05AM	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib (GlobeNewswire) +8.45%
12:00PM	Loading…
Jan-22-24 12:00PM	Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-16-24 04:05PM	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli (GlobeNewswire) +10.69%
Dec-19-23 08:30AM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Dec-04-23 08:35AM	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Nov-14-23 04:30PM	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire)
Nov-07-23 09:28AM	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 (GlobeNewswire)
08:00AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment (GlobeNewswire) +5.92%
Oct-04-23 08:30AM	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy (GlobeNewswire) -26.43%
Sep-20-23 08:30AM	Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity (GlobeNewswire) +17.82%
Aug-24-23 08:30AM	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib (PR Newswire)
Aug-22-23 08:05AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire) -10.33%
Aug-21-23 08:30AM	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib (PR Newswire)
Aug-17-23 08:30AM	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro (PR Newswire)
Aug-15-23 11:47PM	Q2 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.02%
04:20PM	Loading…
Aug-14-23 04:20PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-07-23 08:05AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 (PR Newswire)
Jul-17-23 04:05PM	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Jun-29-23 09:29AM	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split (PR Newswire)
Jun-22-23 08:05AM	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study (PR Newswire) +9.64%
Jun-21-23 08:05AM	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease (PR Newswire)
May-30-23 08:05AM	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII (PR Newswire)
May-24-23 12:04PM	Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology (News Direct)
May-17-23 06:11AM	Inhibikase Therapeutics First Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
May-16-23 07:45AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
May-15-23 08:30AM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (PR Newswire) +7.72%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:05AM	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 (PR Newswire)
May-04-23 08:05AM	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) +6.62%
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 08:00AM	Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease (PR Newswire) -7.90%
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.42%
Apr-21-23 08:30AM	Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase (PR Newswire)
Apr-07-23 10:25PM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 08:22AM	Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-23-23 05:15PM	Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 (PR Newswire) +8.66%
Mar-21-23 08:00AM	Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (PR Newswire)
Mar-16-23 08:30AM	Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023 (PR Newswire)
Mar-15-23 08:35AM	Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
Mar-08-23 08:30AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy (PR Newswire)
Feb-15-23 04:05PM	Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire) +7.81%
Feb-08-23 01:00PM	Inhibikase Therapeutics raises $10M as disease treatments show success (American City Business Journals) +5.25%
Jan-27-23 04:05PM	Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules (PR Newswire) -7.32%
Jan-25-23 01:00PM	Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire) -5.49%
08:35AM	Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders (PR Newswire)
08:05AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease (PR Newswire)
Dec-12-22 04:05PM	Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro (PR Newswire) +5.80%
Dec-07-22 04:05PM	Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs (PR Newswire)
Nov-22-22 08:00AM	Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-14-22 05:45PM	Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire) +8.52%
Nov-10-22 05:00AM	The Petri Dish: Biogen's CEO search stalls again; A setback for Verve (American City Business Journals)
Nov-08-22 08:00AM	Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (PR Newswire) +5.49%
Nov-07-22 08:00AM	Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs (PR Newswire) -40.91%
Oct-12-22 08:00AM	Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference (PR Newswire)
Sep-21-22 04:05PM	Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference (PR Newswire)
Sep-15-22 08:00AM	Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress (PR Newswire) +12.11%
Sep-13-22 12:15PM	Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation (Simply Wall St.)
Sep-08-22 08:30AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Sep-01-22 04:05PM	Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors (PR Newswire)
Aug-26-22 08:00AM	Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia (PR Newswire) +9.51%
Aug-23-22 08:00AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire) +10.51%
Aug-12-22 04:55PM	Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-08-22 08:30AM	Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022 (PR Newswire) +13.58%
Jun-13-22 08:00AM	Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review (PR Newswire) -6.01%
May-16-22 05:00PM	Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
May-10-22 08:05AM	Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference (PR Newswire) -11.10%
May-09-22 04:05PM	Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (PR Newswire) -10.48%
Apr-21-22 04:05PM	Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference (PR Newswire)
Apr-13-22 11:45AM	Vetoquinol: Q1 2022 Sales: 135M (Business Wire)
Apr-06-22 11:37AM	Is Inhibikase Therapeutics (NASDAQ:IKT) In A Good Position To Invest In Growth? (Simply Wall St.) +7.69%
08:00AM	Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 (PR Newswire)
Mar-31-22 05:00PM	Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-28-22 08:00AM	Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit (PR Newswire)
Mar-25-22 08:00AM	Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 (PR Newswire)
Mar-23-22 08:00AM	Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference (PR Newswire)
Mar-08-22 08:00AM	Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD Alzheimer's & Parkinson's Diseases Conference (PR Newswire) +12.62%
Jan-05-22 08:30AM	Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones (PR Newswire) -8.54%
Nov-29-21 08:05AM	Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease (PR Newswire)
Nov-15-21 05:30PM	Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity (PR Newswire)
Oct-27-21 08:05AM	Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit (PR Newswire)
Oct-19-21 08:05AM	Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 (PR Newswire) +9.71%
Oct-04-21 09:57AM	Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate (Benzinga)
08:05AM	Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease (PR Newswire)
Sep-23-21 08:05AM	Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy (PR Newswire)
Sep-07-21 08:00AM	Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

IKT

Inhibikase Therapeutics Inc

Upgrade your FINVIZ experience